Hepatocellular carcinoma is a highly heterogeneous disease. Treatment strategies for advanced hepatocellular carcinoma are limited. Phosphatidylinositol proteoglycan 3 (GPC3) is a heparan sulfate glycoprotein (HSPG) on the surface of the cell membrane. It is highly expressed in liver cancer tissues, but hardly expressed in normal liver tissues. It is an ideal target for tumor treatment. Investigators aimed to test the safety and efficacy of GPC3 CAR-T cells in patients with advanced hepatocellular carcinoma.
40~70 years old;
Patients with advanced hepatocellular carcinoma (HCC) diagnosed by histopathology or cytology, who are not suitable for surgery or local treatment (including ablation therapy, interventional therapy and radiotherapy), and who have experienced progress or intolerance after receiving standard treatment in the past;
Patients who have been terminated for more than 28 days due to previous ineffective PD-1 monoclonal antibody treatment;
At least one target lesion that can be evaluated stably according to RECIST 1.1 standard is defined as: the longest diameter of non lymph node lesions ≥ 10mm, or the short diameter of lymph node lesions ≥ 15mm; Intrahepatic lesions require enhanced imaging in arterial phase;
Pregnant or lactating women;
HCV-RNA, HIV antibody or syphilis antibody are positive;
Any uncontrollable active infection, including but not limited to active tuberculosis;
Have received systemic steroids equivalent to>15 mg prednisone within 2 weeks before single collection, except inhaled steroids;
Single group
GPC3 CAR-T cells
Biological/Vaccinepatients treated with GPC3 CAR-T cells
AE/SAE
adverse event/sever adverse event
ORR
overall response rate
Click on the lead sponsor to view all of their trials.
